2014

Myriant Corporation Files Registration Statement for Proposed Initial Public Offering

QUINCY, Mass., May 31, 2011 /PRNewswire/ -- Myriant Corporation ("Myriant", formerly known as Myriant Technologies Inc.), an industrial biotech company focused on production of biochemicals that substitute for petroleum-based industrial chemicals, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. All of the shares of common stock to be sold in the proposed offering would be sold by Myriant.

(Logo:  http://photos.prnewswire.com/prnh/20110531/NE11071LOGO )

UBS Securities LLC, J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Piper Jaffray & Co. will be acting as joint bookrunning managers, with Morgan Joseph TriArtisan LLC acting as co-manager, for the offering. This offering will be made only by means of a prospectus. Copies of the preliminary prospectus for this offering may be obtained, when available, from the prospectus department of UBS Securities LLC, Attention: Prospectus Department, 299 Park Avenue, New York, New York 10171 or via telephone at 1-888-827-7275; from the prospectus department of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717 or via telephone at 1-866-803-9204; from the prospectus department of Citigroup Global Markets Inc., Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, New York 11220, via telephone at 1-800-831-9146 or email at batprospectusdept@citi.com; or from the prospectus department of Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, Suite 800, Minneapolis, Minnesota 55402, via telephone at 1-612-303-8290 or email at prospectus@pjc.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall neither constitute an offer to sell nor a solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Myriant uses proprietary biotechnology to develop high-value chemicals from low-cost sugars.  Myriant is headquartered in Quincy, Massachusetts.

Contact:
Samuel G. McConnell, Sr.VP, Corporate Development
Telephone:  (617) 657-5207
Email: smcconnell@myriant.com

SOURCE Myriant Corporation




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.